{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:43:19Z","timestamp":1768466599123,"version":"3.49.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.pupt.2019.101874","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T10:45:35Z","timestamp":1576493135000},"page":"101874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study"],"prefix":"10.1016","volume":"60","author":[{"given":"Francesco","family":"Menzella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Galeone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Bagnasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Catellani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Facciolongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2019.101874_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","article-title":"Eosinophilic and non-eosinophilic asthma","volume":"197","author":"Carr","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2019.101874_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2010.11.037","article-title":"Asthma endotypes: a new approach to classificationof disease entities within the asthma syndrome","volume":"127","author":"Lotvall","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2019.101874_bib3","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaip.2019.03.022","article-title":"Targeted therapies for uncontrolled asthma","volume":"5","author":"CorrenNew","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.pupt.2019.101874_bib4","first-page":"5698212","article-title":"Anti-IL-5 and IL-5Ra: efficacy and safety of new therapeutic strategies in severe uncontrolled asthma","author":"Bagnasco","year":"2018","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.pupt.2019.101874_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2018.10.016","article-title":"The severe asthma network in Italy: findings and perspectives","volume":"7","author":"Heffler","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.pupt.2019.101874_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and the treatment of severe asthma\u201d","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2019.101874_bib8","doi-asserted-by":"crossref","first-page":"212561","DOI":"10.7573\/dic.212561","article-title":"Severe refractory asthma: current treatment options and ongoing research","volume":"7","author":"Menzella","year":"2018","journal-title":"Drugs Context"},{"key":"10.1016\/j.pupt.2019.101874_bib9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/02770903.2017.1322611","article-title":"Biologic treatment eligibility for real-world patients with seer asthma: the IDEAL study","volume":"55","author":"Albers","year":"2018","journal-title":"J. Asthma"},{"key":"10.1016\/j.pupt.2019.101874_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13223-018-0301-6","article-title":"Eligibility of monoclonal antibody-based therapy for patients with severe asthma: a Canadian cross-sectional perspective","volume":"14","author":"Jeimy","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"10.1016\/j.pupt.2019.101874_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1164\/rccm.200903-0354OC","article-title":"Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial","volume":"181","author":"Castro","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2019.101874_bib12","article-title":"Safety and effectiveness of bronchial thermoplasty when FEV1 is less than 50","author":"Langton","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2019.101874_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12890-017-0554-8","article-title":"Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma","volume":"18","author":"Facciolongo N","year":"2018","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.pupt.2019.101874_bib14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.anai.2018.01.030","article-title":"Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma","volume":"120","author":"Chipps","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.pupt.2019.101874_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12931-018-0746-7","article-title":"Factors associated with bronchiectasis in patients with uncontrolled asthma; the NOPES score: a study in 398 patients","volume":"19","author":"Padilla-Galo","year":"2018","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2019.101874_bib16","first-page":"5","article-title":"Severe asthma and bronchiectasis","volume":"1","author":"Garc\u00eda-Clemente","year":"2019","journal-title":"J. Asthma"},{"key":"10.1016\/j.pupt.2019.101874_bib17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/14712598.2019.1623875","article-title":"Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Ennis","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.pupt.2019.101874_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pharmthera.2016.06.016","article-title":"Patient stratification and unmet need in asthma","volume":"169","author":"Swedin","year":"2017","journal-title":"Pharmacol. Ther."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553919302202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553919302202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:28:42Z","timestamp":1761082122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553919302202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":17,"alternative-id":["S1094553919302202"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2019.101874","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2019.101874","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101874"}}